Open house drug discount agreements Eptinezumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eptinezumab, ATC N02CD05

50/100

Score d'opportunité

Needs reviewLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

This open house model is explicitly not subject to public procurement law. Legal recourse differs (social courts instea...

No indication of volumes or expected revenue – financial risk without guaranteed sales.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Moderate opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Apr 2028
Non-exclusive discount agreements for the pharmaceutical product Eptinezumab (ATC N02CD05).
Open house model – no competitive selection, all eligible companies can join.

Afficher le résumé complet

Open house (non-procurement law) for non-exclusive discount agreements on the active ingredient Eptinezumab (ATC N02CD05) with AOK Bayern. Contracts can be concluded at any time until 03.03.2028, with earliest start on 01.05.2026 and end on 30.04.2028. All interested pharmaceutical companies meeting the eligibility criteria can participate; no selection occurs.

Risques

This open house model is explicitly not subject to public procurement law. Legal recourse differs (social courts instea...

No indication of volumes or expected revenue – financial risk without guaranteed sales.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical company (pharmazeutisches Unternehmen).
Provide signed contract and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Administrative

Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria (open house model).

Acheteur

Nom

AOK Bayern - Die Gesundheitskasse

Localisation

München, DEU

[email protected]

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Eptinezumab

Non-exclusive discount agreements for Eptinezumab (ATC N02CD05). Contracts run with all eligible pharmaceutical companies. Monthly cutoff for contract start is the 3rd of each month.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria (open house model).

Date limite

Deadline Mar 03, 2028

Détails de la procédure

Date de publication: 15 Mar 2026
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 178615-2026

Documents (2)

Document de consultation 1 Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3